PROCEADE PanTumor: A phase 1b/2, multicenter study of precemtabart tocentecan (M9140), an anti-CEACAM5 antibody-drug conjugate (ADC) with exatecan payload, in patients with advanced solid tumors.

Authors: Zev A. Wainberg, Benjamin Besse, Athanasios G. Pallis, Christina Habermehl, Ken Kato

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps3165

Source: Full article

---

Abstract

TPS3165